• 1
    Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15: 46778
  • 2
    Robertson C, Link CL, Onel E et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007; 99: 34754
  • 3
    Wei JT, Schottenfeld D, Cooper K et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol 2001; 165: 15215
  • 4
    Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 46971
  • 5
    Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: LitwinMS, SaigalCS eds, Urologic Diseases in America (NIH Publication No. 04-5512). Washington DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Government Publishing Office, 2004; 4367
  • 6
    Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 42836
  • 7
    Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 27784
  • 8
    Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 173: 130913
  • 9
    Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007; 52: 96472
  • 10
    Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 2008; 9: 2728
  • 11
    St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164: 7608
  • 12
    Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008; 19: 11321
  • 13
    Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993; 42: 66371
  • 14
    Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 26674
  • 15
    Barry MJ, Fowler FJ Jr, O’Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 154957
  • 16
    Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40–79 years old. J Urol 1999; 161: 11749
  • 17
    Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 8604
  • 18
    Roger VL, Jacobsen SJ, Weston SA et al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmsted County, Minnesota, 1979–1994. Ann Intern Med 2002; 136: 3418
  • 19
    Roger VL, Killian J, Henkel M et al. Coronary disease surveillance in Olmsted County objectives and methodology. J Clin Epidemiol 2002; 55: 593601
  • 20
    Arciero TJ, Jacobsen SJ, Reeder GS et al. Temporal trends in the incidence of coronary disease. Am J Med 2004; 117: 22833
  • 21
    Goraya TY, Jacobsen SJ, Belau PG, Weston SA, Kottke TE, Roger VL. Validation of death certificate diagnosis of out-of-hospital coronary heart disease deaths in Olmsted County, Minnesota. Mayo Clin Proc 2000; 75: 6817
  • 22
    Mills IW, Crossland A, Patel A, Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 2007; 52: 5039
  • 23
    Stamatiou KN, Zaglavira P, Skolarikos A, Sofras F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 2008; 34: 55561
  • 24
    Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 15118
  • 25
    Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005; 173: 19235
  • 26
    Breau RH, Karnes J, Jacobson DJ et al. The association between statin use and the diagnosis of prostate cancer in a population-based cohort. J Urol 2010; 184: 494500
  • 27
    Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008; 101: 3138
  • 28
    Kristal AR, Arnold KB, Schenk JM et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007; 177: 1395400
  • 29
    Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005; 29: 31016
  • 30
    Joseph MA, Harlow SD, Wei JT et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157: 90614
  • 31
    Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006; 68: 1198205
  • 32
    Burke JP, Rhodes T, Jacobson DJ et al. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol 2006; 164: 416
  • 33
    Temml C, Obermayr R, Marszalek M, Rauchenwald M, Madersbacher S, Ponholzer A. Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 2009; 73: 5448
  • 34
    Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 93544
  • 35
    Sarma AV, Burke JP, Jacobson DJ et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008; 31: 47682
  • 36
    Panser LA, Chute CG, Guess HA et al. The natural history of prostatism: the effects of non-response bias. Int J Epidemiol 1994; 23: 1198205
  • 37
    Gades NM, Jacobson DJ, McGree ME et al. Dropout in a longitudinal, cohort study of urologic disease in community-based men. BMC Med Res Methodol 2006; 6: 58
  • 38
    Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008; 7: 71725